Permanent disabilities in childhood survivors of Langerhans cell histiocytosis

Pediatric Hematology and Oncology

Volumn 17, Issue 5, 2000, Pages 375-381

  Kusumakumary, P ^a   James, F V ^a  

^a REGIONAL CANCER CENTRE   (India)

Author keywords

Diabetes insipidus; Growth retardation; Langerhans cell histiocytosis; Permanent disabilities

Indexed keywords

ARTICLE; CHILD; CLINICAL ARTICLE; DIABETES INSIPIDUS; EXOPHTHALMOS; FACIAL NERVE PARALYSIS; GROWTH RETARDATION; HEARING LOSS; HISTIOCYTOSIS X; HUMAN; JAW MALFORMATION; PERIODONTAL DISEASE; PHYSICAL DISABILITY;

EID: 0033932861     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010050034300     Document Type: Article

References (33)

1. Matus-Ridley M, Raney RB, Meadows AT. Histiocytosis X in children: patterns of disease and results of treatment. Med Pediatr Oncol. 1983;11:99-105.
2. Ceci A, Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Co-operative AIEOP-CNR-HX 83 Study. Med Pediatr Oncol. 1993;21:259-264.
3. McLelland J, Broadbent V, Yeomans E, Malone M, Pritchard J. Langerhans cell histiocytosis: the case for conservative management. Arch Dis Child. 1990;65:301-303.
4. Raney RB, D'Angio GJ. Langerhans cell histiocytosis (histiocytosis-X) experience at Children's Hospital of Philadelphia, 1970-1984. Med Pediatr Oncol. 1989;17:20-28.
5. Kusumakumary P, Rajeevkumar S, James FV, Chellam VG, Nair MK, Warrier RP. Langerhans cell histiocytosis in children: patterns of disease and treatment results in Kerala. Int J Pediatr Hematol Oncol. 1996;3:297-303.
6. Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis: evolution and current approaches. Br J Cancer. 1994;23(suppl):S41-S46.
7. Gadner H, Heitbeg A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1994;23:72-80.
8. Kusumakumary P, Priyakumari T, Chellam VG, James FV, Nair MK. Langerhans cell histiocytosis in children less than 2 years of age. Indian Pediatr. 1999;36:29-36.
9. Berry DH, Gresik MV, Humphry B, et al. Natural history of histiocytosis-X: a Pediatric Oncology Group study. Med Pediatr Oncol. 1986;14:1-5.
10. Dunger DB, Broadbent V, Yeoman E, et al. The frequency and natural history of diabetes insipidus in children with Langerhans cell histiocytosis. N Engl J Med. 1989;321:1157-1162.
11. Greenberger JS, Crocker AC, Vawter G, Jaffe N, Cassady JR. Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome, Schuller-Christian syndrome and multifocal eosinophilic granuloma). Medicine. 1984;60:311-388.
12. Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay K. Disease course and late sequelae of Langerhans cell histioytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14:2073-2082.
13. Komp DM, Elmahdi A, Starling KA, et al. Quality of survival in histiocytosis X: a Southwest Oncology Group study. Med Pediatr Oncol. 1980;8:35-40.
14. Sims DG. Histocytosis-X: follow up of 43 cases. Arch Dis Child. 1977;52:433-440.
15. Cline MJ. Histiocytes and histiocytosis. Blond. 1994;84:2840-2853.
16. Alessi DM, Maceri D. Histiocytosis-X of the head and neck in a pediatric population. Arch Otolaryngol Head Neck Surg. 1992;118:945-948.
17. Filocoma D, Needleman HL, Arceci R, Gelber RD, Donnelly M. Pediatric histiocytosis-X. Am J Pediatr Hematol Oncol. 1992;15:226-230.
18. Grois N, Flucher-Wolfram B, Heitger A, Mostbeck GH, Hofmann J, Gadner H. Diabetes insipidus in Langerhans cell histiocytosis: results from DAL HX-83 study. Med Pediatr Oncol. 1995;24:248-256.
19. Ladisch S, Gadner H, Arico M, et al. LCH-I A randomized trial of etoposide vs vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1994;23:107-110.
20. Favara BE. Langerhans cell histiocytosis: pathobiology and pathogenesis. Sem Oncol. 1991;18:3-7.
21. Scherbaum WA, Wass JAH, Besser GM Bottazzo GF, Doniach D. Antoimmune cranial diabetes insipidus: its association with other endocrine diseases and with histiocytosis X. Clin Endocrinol. 1986;25: 411-420.
22. Fujsawa I, Nishimura K, Asato R, Tageshi K, Itosh R, Noma S. Posterior lobe of pituitary in diabetes insipidus: MR findings. J Comput Assist Tomogr. 1987;11:221-225.
23. Rosenfield NS, Abrahams J, Romp D. Brain MR in patients with Langerhans cell histiocytosis: findings and enhancement with FD-DTPA. Pediatr Radiol 1990;20:433-436.
24. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer. 1994;70(Suppl):S37-S40.
25. Rosenzweig KE, Arceci RJ, Tarbell NJ. Diabetes insipidus secondary to Langerhans cell histiocytosis: Is radiation therapy indicated? Med Pediatr Oncol. 1997;29:36-40.
26. Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: Is it reversible? Med Pediatr Oncol. 1997;28:289-293.
27. Minehan KJ, Chen MG, Zimmerman D, Su JQ, Colby TV, Shaw KG. Radiation therapy for diabetes insipidus caused by Langerhans cell histioytosis. Int J Radiat Oncol Biol Phys. 1992;23:519-524.
28. Broadbent V, Pritchard J, Yeoman E. Etoposide in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X). Med Pediatr Oncol. 1989;17:97-100.
29. Ceci A, Terlizzi M, Balducci D, et al. Etoposide in recurrent childhood Langerhans cell histiocytosis: an Italian co-operative study. Cancer. 1988;62:2528-2531.
30. Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:287-305.
31. Arico M, Egeler M. Clinical aspects of Langerhans cell histiocytsis. Hematol Oncol Clin North Am. 1998;12:247-258.
32. Ha SY, Helms P, Fletcher M, Broadbent V, Pritchard J. Lung involvement in Langerhans cell histiocytosis: prevalence, clinical features and outcome. Pediatrics. 1992;89:466-469.
33. Egeler RM, Neglia J, Puccetti DM, Brennan C, Nesbit ME. The association of Langerhans cell histiocytosis with malignant neoplasms. Cancer. 1993;71:865-873.